GTBP GT Biopharma Corp: Net earnings per one share for the last twelve months

Public company logo of GT Biopharma Corporation (GTBP)

In the immuno-oncology sector, GT Biopharma, Inc. (GTBP) faces fierce competition and regulatory pressure. The EPS YoY TTM percentage trend demonstrates current earnings resilience, with the current value equal to 59.70. The company is implementing the TriKE platform for NK-cell activation, bypassing costly CAR-T. Drug selection efficiency is increasing through automated protein modeling and robotic testing.

GT Biopharma Inc (GTBP): Net earnings per share (EPS TTM) from 02/11/2024 to 11/18/2026

Financial and market metric breakdowns for GT Biopharma Corp (GTBP)

- share price and expert price forecast:
Fundamental valuation:GT Biopharma GTBP
Signature product of GT Biopharma Inc

Selecting assets with a high margin of safety begins with an analysis of profit dynamics. This indicator captures the annual growth rate of rolling net earnings per share, reflecting the market consensus regarding business efficiency. For GT Biopharma, Inc. (GTBP), which is developing innovative TriKE drugs, this metric measures the monetization speed of its oncological developments. By analyzing the year-over-year EPS history (TTM), an investor determines the company's readiness for scaling.